INT16616

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 44
Total Number 44
Disease Relevance 34.81
Pain Relevance 2.96

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (SRD5A1) small molecule metabolic process (SRD5A1) endoplasmic reticulum (SRD5A1)
cytoplasm (SRD5A1)
Anatomy Link Frequency
hypothalamus 1
hair follicles 1
pituitary 1
SRD5A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 346 99.96 Very High Very High Very High
cINOD 40 97.56 Very High Very High Very High
Inflammation 61 96.88 Very High Very High Very High
withdrawal 44 95.24 Very High Very High Very High
depression 134 89.92 High High
cryotherapy 1 89.04 High High
Calcium channel 5 86.96 High High
corticosteroid 10 83.76 Quite High
Potency 19 81.40 Quite High
Catecholamine 8 77.04 Quite High
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 2427 99.96 Very High Very High Very High
Overactive Bladder 946 99.96 Very High Very High Very High
Prostate Cancer 398 99.96 Very High Very High Very High
Reprotox - General 1 345 99.26 Very High Very High Very High
Hematuria 93 99.22 Very High Very High Very High
Cancer 136 99.20 Very High Very High Very High
Disease 179 99.08 Very High Very High Very High
Hyperplasia 25 98.66 Very High Very High Very High
Lower Urinary Tract Symptoms 756 97.72 Very High Very High Very High
Diuresis 256 97.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The role of 5-alpha-reductase inhibitors
Negative_regulation (inhibitors) of 5-alpha-reductase
1) Confidence 0.57 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 0.81 Pain Relevance 0
Medical treatments have been developed since 1980 which inhibit the course of BPH and minimize some of the clinical symptoms: plant extracts, alpha-blockers, 5-alpha-reductase inhibitors.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy
2) Confidence 0.57 Published 1996 Journal Ann Urol (Paris) Section Abstract Doc Link 9092383 Disease Relevance 0.64 Pain Relevance 0.14
Role of 5-alpha reductase inhibitors in AUR
Negative_regulation (inhibitors) of 5-alpha reductase associated with overactive bladder
3) Confidence 0.57 Published 2007 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2721562 Disease Relevance 1.26 Pain Relevance 0
Theoretically, there seem to be several possibilities to improve the current treatment, which is based mainly on alpha1-adrenoceptor (AR) antagonists, 5alpha-reductase inhibitors and phytotherapy.
Negative_regulation (inhibitors) of 5alpha-reductase associated with antagonist
4) Confidence 0.57 Published 2002 Journal World J Urol Section Abstract Doc Link 12022712 Disease Relevance 0.53 Pain Relevance 0.24
The MTOPS data demonstrates that the improvements in Qmax and AUASS achieved by 5-alpha-reductase inhibitor and alpha-adrenergic receptor antagonist combination therapy are significantly greater than either alone.
Negative_regulation (inhibitor) of 5-alpha-reductase associated with antagonist
5) Confidence 0.57 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.68 Pain Relevance 0.21
One such strategy is to administer a higher dose of testosterone with the addition of a 5-alpha reductase inhibitor to prevent the prostate symptoms.
Negative_regulation (inhibitor) of 5-alpha reductase
6) Confidence 0.42 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2686341 Disease Relevance 0.46 Pain Relevance 0.03
These studies also confirmed the PLESS finding of decreased BPH progression in patients being treated with 5-alpha-reductase inhibitors.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy
7) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.96 Pain Relevance 0.03
The initial form of therapy for BPH is medical, especially in patients with mild-moderate symptoms and no clear indication for surgical intervention.11 Current accepted medical therapy consists of alpha-adrenergic receptor antagonists, 5-alpha-reductase inhibitors, or a combination.


Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy and antagonist
8) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.46 Pain Relevance 0.18
Elevated levels of DHT, along with hypothesized hormonal imbalances, result in BPH.2,5 The lack of prostate growth and resultant BPH or prostate cancer in male pseudohermaphrodites due to 5-alpha-reductase deficiency was first reported in 1974.6,7 These observations were the rationale for the use of 5-alpha-reductase inhibitors in the treatment of BPH.
Negative_regulation (deficiency) of 5-alpha-reductase associated with benign prostatic hypertrophy and reprotox - general 1
9) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.16 Pain Relevance 0.10
Medical therapy gained acceptance about two decades ago with the approval of alpha-adrenergic receptor antagonists and 5-alpha-reductase inhibitors for the treatment of symptomatic BPH.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy and antagonist
10) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.62 Pain Relevance 0.10
The first of these to be approved for use by the FDA for treatment of BPH was finasteride, a potent competitive inhibitor of 5-alpha-reductase that shows no affinity for the androgen receptor.32 This drug inhibits the type 2 isoenzyme of 5-alpha-reductase, which is present at high levels in the prostate.
Negative_regulation (inhibitor) of 5-alpha-reductase associated with benign prostatic hypertrophy
11) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.31 Pain Relevance 0.07
Elevated levels of DHT, along with hypothesized hormonal imbalances, result in BPH.2,5 The lack of prostate growth and resultant BPH or prostate cancer in male pseudohermaphrodites due to 5-alpha-reductase deficiency was first reported in 1974.6,7 These observations were the rationale for the use of 5-alpha-reductase inhibitors in the treatment of BPH.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy and reprotox - general 1
12) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.20 Pain Relevance 0.11
Dutasteride, because of dual inhibition of 5-alpha-reductase, results in a greater than 90% decrease in serum DHT levels.40 Three parallel, multicenter, randomized, placebo-controlled trials of 24 monthsÂ’ duration have examined the safety and efficacy of dutasteride in men with BPH.40 All three studies included men 50 years or older with a clinical diagnosis of BPH, a transrectal ultrasonography (TRUS) prostate volume greater than 30mL, AUASS of 12 or more, and Qmax of 15 mL/sec or less.
Negative_regulation (inhibition) of 5-alpha-reductase associated with benign prostatic hypertrophy
13) Confidence 0.42 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.43 Pain Relevance 0
Cancer chemopreventive approaches may include 5-alpha-reductase inhibitors, histone deacetylase inhibitors, antioxidans, non-steroidal anti-inflammatory drugs, cholesterol-lowering statins, vitamin D analogues.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with inflammation, cancer and cinod
14) Confidence 0.42 Published 2010 Journal Eur Rev Med Pharmacol Sci Section Abstract Doc Link 20184087 Disease Relevance 1.17 Pain Relevance 0.10
Recent studies demonstrate that 5-alpha-reductase inhibitors are effective in the treatment of BPH-induced hematuria,41 probably through their effect on prostate microvessel density.42 Multiple studies now support the role of short-term 5-alpha-reductase inhibitor monotherapy prior to definitive surgical resection in order to decrease hematuria during and after the procedure.43,44

5-alpha-reductase inhibitor and alpha-adrenergic receptor antagonist combination therapy

Negative_regulation (inhibitor) of 5-alpha-reductase associated with benign prostatic hypertrophy, antagonist and hematuria
15) Confidence 0.41 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.89 Pain Relevance 0.05
Recent studies demonstrate that 5-alpha-reductase inhibitors are effective in the treatment of BPH-induced hematuria,41 probably through their effect on prostate microvessel density.42 Multiple studies now support the role of short-term 5-alpha-reductase inhibitor monotherapy prior to definitive surgical resection in order to decrease hematuria during and after the procedure.43,44

5-alpha-reductase inhibitor and alpha-adrenergic receptor antagonist combination therapy

Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy, antagonist and hematuria
16) Confidence 0.41 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 1.19 Pain Relevance 0.04
Because androgens are required for the development of prostate cancer[48] and men with lower 5-alpha-reductase activity have lower rate of prostate cancer, 5-alpha-reductase inhibitors have been considered for chemo-prevention of prostate cancer. 5-alpha-reductase inhibitors decrease the prostate levels of dihydrotestosterone and reduce the androgenic stimulation to the prostate, although the systemic androgenic effects are only mildly affected.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with prostate cancer
17) Confidence 0.41 Published 2008 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2684344 Disease Relevance 0.92 Pain Relevance 0
Summary: 5-alpha-reductase inhibitors such as finasteride and dutasteride have been recommended as chemotherapeutic agents for prevention of prostate cancer.


Negative_regulation (inhibitors) of 5-alpha-reductase associated with prostate cancer
18) Confidence 0.41 Published 2008 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2684344 Disease Relevance 0.57 Pain Relevance 0
It is well known that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of prostate and is 10 times more potent than testosterone. 5-alpha-reductase inhibitors prevent the conversion of testosterone to dihydrotestosterone.
Negative_regulation (prevent) of 5-alpha-reductase associated with hyperplasia
19) Confidence 0.41 Published 2008 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2684344 Disease Relevance 0.99 Pain Relevance 0.33
5-alpha-reductase inhibitors are the only therapy that alter the underlying disease process and prevent BPH disease progression.
Negative_regulation (inhibitors) of 5-alpha-reductase associated with benign prostatic hypertrophy, disease and disease progression
20) Confidence 0.41 Published 2008 Journal International Journal of Clinical Practice Section Body Doc Link PMC2440415 Disease Relevance 1.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox